MA55203A - Inhibiteurs d'azétidinyl 0-glyc0pr0téin-2-acétamid0-2-désoxy-3-d-gluc0pyran0sidase - Google Patents
Inhibiteurs d'azétidinyl 0-glyc0pr0téin-2-acétamid0-2-désoxy-3-d-gluc0pyran0sidaseInfo
- Publication number
- MA55203A MA55203A MA055203A MA55203A MA55203A MA 55203 A MA55203 A MA 55203A MA 055203 A MA055203 A MA 055203A MA 55203 A MA55203 A MA 55203A MA 55203 A MA55203 A MA 55203A
- Authority
- MA
- Morocco
- Prior art keywords
- acetamid0
- desoxy
- azetidinyl
- inhibitors
- Prior art date
Links
- -1 AZETIDINYL Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962815553P | 2019-03-08 | 2019-03-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA55203A true MA55203A (fr) | 2022-01-12 |
Family
ID=69960768
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA055203A MA55203A (fr) | 2019-03-08 | 2020-03-06 | Inhibiteurs d'azétidinyl 0-glyc0pr0téin-2-acétamid0-2-désoxy-3-d-gluc0pyran0sidase |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US12421224B2 (fr) |
| EP (1) | EP3935055A1 (fr) |
| JP (1) | JP7663503B2 (fr) |
| MA (1) | MA55203A (fr) |
| WO (1) | WO2020185593A1 (fr) |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| EP2780013A4 (fr) | 2011-11-18 | 2015-07-01 | Constellation Pharmaceuticals Inc | Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées |
| US9206128B2 (en) | 2011-11-18 | 2015-12-08 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| WO2013078320A1 (fr) | 2011-11-21 | 2013-05-30 | Constellation Pharmaceuticals | Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées |
| US9085583B2 (en) | 2012-02-10 | 2015-07-21 | Constellation—Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| MA38341B1 (fr) | 2013-02-11 | 2018-11-30 | Constellation Pharmaceuticals Inc | Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées |
| PL2970272T3 (pl) | 2013-03-14 | 2019-09-30 | Merck Patent Gmbh | Inhibitory glikozydazowe |
| EP2970305B1 (fr) | 2013-03-15 | 2017-02-22 | Constellation Pharmaceuticals, Inc. | Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées |
| WO2015023915A1 (fr) | 2013-08-15 | 2015-02-19 | Constellation Pharmaceuticals, Inc. | Dérivés d'indole utilisés en tant que modulateurs d'enzymes de modification du méthyle, compositions et utilisations associées |
| WO2018109202A1 (fr) * | 2016-12-16 | 2018-06-21 | Janssen Pharmaceutica Nv | Composés inhibiteurs d'oga monocyclique |
| EP3585790A1 (fr) * | 2017-02-27 | 2020-01-01 | Janssen Pharmaceutica NV | Dérivés de [1,2,4]-triazolo [1,5-a]-pyrimidinyle substitués par de la pipéridine, de la morpholine ou de la pipérazine utilisés en tant qu'inhibiteurs d'oga |
-
2020
- 2020-03-06 EP EP20714094.8A patent/EP3935055A1/fr active Pending
- 2020-03-06 WO PCT/US2020/021479 patent/WO2020185593A1/fr not_active Ceased
- 2020-03-06 US US17/435,125 patent/US12421224B2/en active Active
- 2020-03-06 JP JP2021552999A patent/JP7663503B2/ja active Active
- 2020-03-06 MA MA055203A patent/MA55203A/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020185593A1 (fr) | 2020-09-17 |
| US12421224B2 (en) | 2025-09-23 |
| US20220259197A1 (en) | 2022-08-18 |
| JP7663503B2 (ja) | 2025-04-16 |
| EP3935055A1 (fr) | 2022-01-12 |
| JP2022524077A (ja) | 2022-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL283639A (en) | Kif18a inhibitors | |
| IL282468A (en) | 2- amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors | |
| MA51616A (fr) | Inhibiteurs d'adn-pk | |
| EP4007752C0 (fr) | Inhibiteurs de kif18a | |
| EP4007753C0 (fr) | Inhibiteurs de kif18a | |
| EP3906026A4 (fr) | Inhibiteurs irréversibles de l'interaction ménine-mll | |
| MA54550A (fr) | Inhibiteurs de kif18a | |
| MA52004A (fr) | Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase | |
| MA44725A (fr) | Formulations d'un inhibiteur de lsd1 | |
| UA42295S (uk) | Комп'ютер | |
| IL304348A (en) | Cd73 inhibitors | |
| MA52812A (fr) | Inhibiteurs de sarm1 | |
| UA42369S (uk) | Комп'ютер | |
| DK3774817T3 (da) | Bcl6-hæmmere | |
| MA49006A (fr) | Inhibiteurs d'ip6k | |
| MA52809A (fr) | Inhibiteurs de sarm1 | |
| MA52813A (fr) | Inhibiteurs de sarm1 | |
| IL308293B2 (en) | Cd73 inhibitors | |
| EP3919491A4 (fr) | Inhibiteur d'akt | |
| EP3980011A4 (fr) | Inhibiteurs de sarm1 | |
| EP3817736A4 (fr) | Inhibiteurs de pikfyve | |
| MA53648A (fr) | Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glucopyranosidase | |
| EP3820980A4 (fr) | Compositions d'esterquats | |
| EP4030778A4 (fr) | Casque d'écoute | |
| EP3765619A4 (fr) | Inhibiteurs de micro-arn 22 |